Background: It remains to be established which factors contribute to the occurrence of asthma in allergic individuals. We hypothesized that differences in the late allergic inflammatory reaction to allergen between asthmatic and non-asthmatic house dust mite-allergic individuals might contribute to the difference in the clinical presentation of allergy. Aim: To compare allergen-induced changes in parameters for cellular inflammation during the phase of the late allergic reaction in the skin and nose, in house dust mite-allergic individuals with or without asthma. Material and Methods: Nasal and dermal allergen challenges with house dust mite (Dermatophagoides pteronyssinus) extract were performed in 52 house dust mite-allergic individuals, of whom 26 had mild to moderate persistent asthma and 26 had perennial rhinitis without current or past asthmatic symptoms. Serial nasal lavage samples were analyzed for the presence of inflammatory cells (eosinophils and neutrophils) and soluble markers associated with cellular inflammation [interleukin-5 (IL-5), interleukin-8 (IL-8), eosinophil cationic protein (ECP) and myeloperoxidase (MPO)]. Macroscopic late phase skin reactions were studied after intracutaneous skin tests with house dust mite extract. Results: Fixed dose nasal allergen provocation elicited a similar degree of immediate allergic reaction as judged by plasma protein exudation and histamine concentrations in asthma and non-asthmatic rhinitis. Subsequently, no differences between groups were found during the phase of the late allergic reaction (4–24 h) in inflammatory cell influx, plasma protein leakage, ECP or MPO. Likewise, there were no differences in levels of chemotactic cytokines IL-5 and IL-8. In agreement with the results of nasal challenge, the late skin reaction after dermal challenge with a fixed allergen dose and after an allergen dose 10,000 times above the skin threshold for an early skin reaction did not differ between the groups. Conclusion: House dust mite-allergic patients with or without asthma have very similar late allergic inflammatory reactions in the skin and in the nose after allergen challenge. Hence, it is unlikely that the occurrence of pulmonary symptoms in asthma is explained by a general tendency of asthmatics to have an enhanced late allergic cellular inflammatory response. Nasal and dermal allergen provocations are adequate models to study allergen-induced inflammation but probably lack the pivotal link which is essential for the development of asthma.

1.
Corren J: Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997;99:S781–S786.
2.
Rowe-Jones JM: The link between the nose and lung, perennial rhinitis and asthma – Is it the same disease? Allergy 1997;52:20–28.
3.
Ramsdale EH, Morris MM, Roberts RS, Hargreave FE: Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985;75:573–577.
4.
Eggleston PA: Upper airway inflammatory diseases and bronchial hyperresponsiveness. J Allergy Clin Immunol 1988;81:1036–1041.
5.
Djukanovic R, Lai CK, Wilson JW, Britten KM, Wilson SJ, Roche WR, Howarth PH, Holgate ST: Bronchial mucosal manifestations of atopy: A comparison of markers of inflammation between atopic asthmatics, atopic nonasthmatics and healthy controls. Eur Respir J 1992;5:538–544.
6.
Shaver JR, O’Connor JJ, Pollice M, Cho SK, Kane GC, Fish JE, Peters SP: Pulmonary inflammation after segmental ragweed challenge in allergic asthmatic and nonasthmatic subjects. Am J Respir Crit Care Med 1995;152:1189–1197.
7.
Polosa R, Ciamarra I, Mangano G, Prosperini G, Pistorio MP, Vancheri C, Crimi N: Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J 2000;15:30–35.
8.
Alvarez MJ, Olaguibel JM, Garcia BE, Rodriquez A, Tabar AI, Urbiola E: Airway inflammation in asthma and perennial allergic rhinitis. Relationship with nonspecific bronchial responsiveness and maximal airway narrowing. Allergy 2000;55:355–362.
9.
Stevens WJ, van Bever HP: Frequency and intensity of late asthmatic reactions after bronchial allergen challenge in asthma and rhinitis. Allergy 1989;44:471–476.
10.
Muller BA, Leick CA, Smith RM, Suelzer MT, Richerson HB: Comparisons of specific and nonspecific bronchoprovocation in subjects with asthma, rhinitis, and healthy subjects. J Allergy Clin Immunol 1993;91:758–772.
11.
Lopuhaa CE, Out TA, Jansen HM, Aalberse RC, van der Zee JS: Allergen-induced bronchial inflammation in house dust mite-allergic patients with or without asthma. Clin Exp Allergy 2002;32:1720–1727.
12.
Garrelds IM, de Graaf-in ‘t Veld T, Nahori MA, Vargaftig BB, Gerth van Wijk R, Zijlstra FJ: Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis patients. Eur J Pharmacol 1995;275:295–300.
13.
Wang D, Smitz J, Derde MP, Clement P: Concentrations of myeloperoxidase in nasal secretions of atopic patients after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1996;110:85–90.
14.
Jacobi HH, Poulsen LK, Reimert CM, Skov PS, Ulfgren AK, Jones I, Elfman LB, Malling HJ, Mygind N: IL-8 and the activation of eosinophils and neutrophils following nasal allergen challenge. Int Arch Allergy Immunol 1998;116:53–59.
15.
Greiff L, Meyer P, Svensson C, Persson CG, Andersson M: The ‘nasal pool’-device for challenge and lavage of the nasal mucosa in children: Histamine-induced plasma exudation responses. Pediatr Allergy Immunol 1997;8:137–142.
16.
Anonymous: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987;136:225–244.
17.
Anonymous: International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy 1994;49:1–34.
18.
Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 1993;48:48–82.
19.
Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NFJ, Meyers DA, Norman PS, Lichtenstein LM: Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128:597–602.
20.
Liu L, Zuurbier AE, Mul FP, Verhoeven AJ, Lutter R, Knol EF, Roos D: Triple role of platelet-activating factor in eosinophil migration across monolayers of lung epithelial cells: Eosinophil chemoattractant and priming agent and epithelial cell activator. J Immunol 1998;161:3064–3070.
21.
Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R: Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilusinfluenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:947–952.
22.
McNamee LA, Fattah DI, Baker TJ, Bains SK, Hissey PH: Production, characterisation and use of monoclonal antibodies to human interleukin-5 in an enzyme-linked immunosorbent assay. J Immunol Methods 1991;141:81–88.
23.
Nocker RE, Schoonbrood DF, Van de Graaf EA, Hack CE, Lutter R, Jansen HM, Out TA: Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 1996;109:183–191.
24.
Van de Graaf EA, Out TA, Roos CM, Jansen HM: Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. Am Rev Respir Dis 1991;143:362–368.
25.
Siraganian RP: Refinements in the automated fluorometric histamine analysis system. J Immunol Methods 1975;7:283–290.
26.
Witteman AM, Stapel SO, Perdok GJ, Sjamsoedin DH, Jansen HM, Aalberse RC, van der Zee JS: The relationship between RAST and skin test results in patients with asthma or rhinitis: A quantitative study with purified major allergens. J Allergy Clin Immunol 1996;97:16–25.
27.
Schuurman J, Perdok GJ, Lourens TE, Parren PW, Chapman MD, Aalberse RC: Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE. J Allergy Clin Immunol 1997;99:545–550.
28.
Greisner WA, Settipane RJ, Settipane GA: Co-existence of asthma and allergic rhinitis: A 23-year follow-up study of college students. Allergy Asthma Proc 1998;19:185–188.
29.
Danielsson J, Jessen M: The natural course of allergic rhinitis during 12 years of follow-up. Allergy 1997;52:331–334.
30.
Fish JE, Ankin MG, Kelly JF, Peterman VI: Comparison of responses to pollen extract in subjects with allergic asthma and nonasthmatic subjects with allergic rhinitis. J Allergy Clin Immunol 1980;65:154–161.
31.
van der Veen MJ, Van Neerven RJ, De Jong EC, Aalberse RC, Jansen HM, van der Zee JS: The late asthmatic response is associated with baseline allergen-specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin-5. Clin Exp Allergy 1999;29/2:217–227.
32.
Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB: Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: Interleukin-8 is not the main chemotactic factor present in nasal lavages. Clin Exp Allergy 1997;27:379–388.
33.
de Graaf-in ‘t Veld C, Garrelds IM, Koenders S, Gerth van Wijk R: Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls. Clin Exp Allergy 1996;26:903–908.
34.
Meyer P, Persson CGA, Andersson M, Wollmer P, Linden M, Svensson C, Greiff L: Alpha2-macroglobulin and eosinophil cationic protein in the allergic airway mucosa in seasonal allergic rhinitis. Eur Respir J 1999;13:633–637.
35.
Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A: Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989;19:701–705.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.